Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
YD BioYDES +15.57%15 Debt-to-EBITDA is -0.00 as of Jun. 2026. GuruFocus rates YDES with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 303 Biotechnology companies, YD Bio ranks worse than 330032.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for YD Bio's Debt-to-EBITDA or its related term are showing as below:
During the past 3 years, the highest Debt-to-EBITDA Ratio of YD Bio was 2.18. The lowest was -0.02. And the median was 0.00.
YDES's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.27 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
YD Bio Debt-to-EBITDA Related Terms
YD Bio Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for YD Bio's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio Debt-to-EBITDA Chart
YD Bio Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-EBITDA
2.18
-0.02
-0.00
YD Bio Semi-Annual Data
Dec23
Dec24
Jun25
Dec25
Jun26
Debt-to-EBITDA
N/A
N/A
-0.01
-0.00
-0.00
YDES vs TTRX, BCYC, FULC: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, YD Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YD Bio Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, YD Bio's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where YD Bio's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
YD Bio (YDES) has a Debt-to-EBITDA of -0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on YD Bio. According to the industry distribution chart, YD Bio ranks #999999 out of 303 companies in the Biotechnology industry.
Is YD Bio's Debt-to-EBITDA too high?
YD Bio's current Debt-to-EBITDA is -0.00. Based on the distribution chart, YD Bio ranks #999999 out of 303 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, YD Bio has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's Debt-to-EBITDA compare to TTRX and BCYC?
According to the Biotechnology industry distribution chart, YD Bio ranks #999999 out of 303 companies for Debt-to-EBITDA. This places YD Bio in the lower half of its industry. The industry median Debt-to-EBITDA is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.27, based on 303 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on YD Bio. For the Biotechnology industry, the median Debt-to-EBITDA is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. YD Bio's current Debt-to-EBITDA is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current Debt-to-EBITDA of -0.00. The current Debt-to-EBITDA is -0.00. YD Bio's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For YD Bio (YDES), the current Debt-to-EBITDA is -0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
15GF Score
Get the complete analysis for YDES
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YDES has been successfully added to your 
